Sep 2026· Journal of Pain & Palliative Care Pharmacotherapy· pp.
1-10
· 0 citations· 28 references
Medicine
TL;DR
Subcutaneous diclofenac and ketorolac may reduce short-term acute pain compared with placebo, however, the evidence is limited and safety remains uncertain.
Abstract
This review aimed to evaluate the efficacy and safety of subcutaneous nonsteroidal anti-inflammatory drugs (NSAIDs).
We searched CENTRAL, MEDLINE, Embase, trial registries, and Google Scholar until December 19, 2024. Eligible studies were randomized controlled trials (RCTs) in adults comparing subcutaneous NSAIDs with other routes of administration, placebo, no treatment, or other drugs. The primary outcome was pain intensity; secondary outcomes were rescue medication use and adverse events. We assessed risk of bias using the Risk of Bias 2 tool. Random-effects meta-analyses used standardized mean differences (SMDs) for pain intensity and odds ratios for rescue medication use. Adverse events were summarized narratively.
Four RCTs (n = 825) were included: three placebo-controlled trials and one route-comparison trial, all evaluating short-term treatment for acute pain with subcutaneous diclofenac or ketorolac. In the meta-analysis of three placebo-controlled trials (n = 500), subcutaneous NSAIDs reduced pain (SMD = 0.72; 95% CI, 0.22 to 1.21; I2 = 82.8%) and rescue medication use. Adverse-event data were limited and inconsistent, with one trial reporting higher event rates with subcutaneous NSAIDs than placebo and another reporting comparable rates. The route-comparison trial showed comparable efficacy and safety between subcutaneous and intramuscular diclofenac.
In conclusion, subcutaneous diclofenac and ketorolac may reduce short-term acute pain compared with placebo. However, the evidence is limited and safety remains uncertain. Further route-comparison studies are needed.
Celecoxib appears to be safe for acute non-cancer pain when compared to placebo, NSAIDS, and opioids, and had a lower risk compared to opioids for gastrointestinal adverse events in general, nausea and vomiting, as well as a lower risk for nausea adverse events when compared to placebo and nsNSAIDS.
Carlos I. Mesa-Castrillon, Ye Tian, J. Hughes et al.· Drugs· 0 citations
Systemic enzyme therapy (SET) has emerged as a potential anti-inflammatory intervention, either as monotherapy or in combination with non-steroidal anti-inflammatory drugs (NSAIDs). Despite its increasing clinical application, the comparative efficacy of SET in various inflammatory conditions remains insufficiently exp...
G. Shivakumar, N. Abdul, Mahesh Shenoy et al.· Dental and Medical Problems· 0 citations
INTRODUCTION
Low back pain, migraine, and other headache disorders are major contributors to disability, and interest in cannabinoid-based interventions has increased despite uncertainty regarding their indication-specific therapeutic value. This systematic review evaluated the efficacy and safety of isolated cannabino...
Claudete da Costa-Oliveira, Magnólia de Jesus Castro, Luiza Aparecida Luna Silvério et al.· Cannabis and Cannabinoid Res...· 0 citations
NSAIDs improved analgesia and reduced opioid use after TORS without significantly increasing POH risk, supporting NSAID integration into postoperative protocols.
Rahul D. Patel, Connor J. Dorais, Tristen Hofmann et al.· Head and Neck· 1 citation
Pharmacological add-on therapies showed no significant efficacy beyond corticosteroids but may improve quality of life, and risk of bias ranged from moderate to high, with low statistical heterogeneity.
F. Thianich, Katharina M. Wörgötter, Linda Bruckner et al.· Acta Dermato-Venereologica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.